Lymphoma is not an autoimmune disease. It is a cancer of the lymphatic system, where immune cells called lymphocytes grow uncontrollably and form tumors. Autoimmune diseases, by contrast, involve an immune system that mistakenly attacks healthy tissue but doesn’t produce cancerous cells. The two are distinct categories of disease. However, the relationship between them is far more intertwined than most people realize, and recent research suggests they may sit on the same biological spectrum.
Why the Two Get Confused
Lymphoma and autoimmune diseases both involve the same cast of characters: lymphocytes, the white blood cells responsible for immune defense. In autoimmune conditions like rheumatoid arthritis or lupus, those cells become “autoreactive,” meaning they target the body’s own tissues. In lymphoma, lymphocytes accumulate genetic damage that causes them to multiply without stopping. The symptoms can look similar too. Swollen lymph nodes, fatigue, and inflammation are hallmarks of both. For someone living with an autoimmune condition who notices new swelling or unexplained weight loss, the overlap is genuinely confusing.
Recent research published in Trends in Immunology has proposed that autoimmune disorders and lymphoid cancers actually share driver mutations and pathological cell states. The same genetic errors found in lymphoma cells have been identified in the autoreactive lymphocytes of people with autoimmune diseases. Certain dysfunctional immune cells, particularly a type called aged or autoimmune memory B cells, appear to be precursors to both conditions. This has led some researchers to frame autoimmunity and lymphoma not as entirely separate diseases but as different outcomes along a shared disease spectrum.
How Autoimmune Disease Raises Lymphoma Risk
Several autoimmune conditions are linked to a higher risk of developing non-Hodgkin lymphoma. The American Cancer Society lists rheumatoid arthritis, lupus, Sjögren disease, and celiac disease among them. The connection is not coincidental. It comes down to what chronic inflammation does to immune cells over time.
Your immune system generates new antibodies through a process that involves cutting and rearranging DNA inside B cells. This is normal and necessary, but it carries inherent risk. Every time a B cell edits its own genetic code to produce a better-fitting antibody, there’s a small chance of something going wrong: a gene segment joins the wrong partner, or a mutation lands in a spot that controls cell growth. In a healthy immune response, these errors are usually caught and repaired. But in autoimmune disease, B cells are chronically stimulated. They go through this DNA-editing process over and over again, year after year, which multiplies the opportunities for a cancer-causing mistake to slip through.
Organs that are normally free of organized immune tissue can develop it as a result of chronic autoimmune inflammation. The salivary glands in Sjögren disease and the thyroid in Hashimoto’s thyroiditis are prime examples. This acquired lymphoid tissue becomes the substrate where malignant transformation can eventually occur. It’s a multistep process involving sustained immune stimulation, genetic instability, and immune deregulation, none of which happens overnight.
Sjögren Disease and MALT Lymphoma
The strongest and best-studied link is between Sjögren disease and a specific subtype called MALT lymphoma (mucosa-associated lymphoid tissue lymphoma). Over 5% of people with Sjögren disease develop B-cell lymphoma, most commonly in the salivary glands where the autoimmune damage is concentrated. That number may sound small, but it represents a dramatically elevated risk compared to the general population.
What’s notable is that while the risk factors for this progression are common among Sjögren patients, only that 5% actually develop lymphoma. Researchers are still working to understand what tips certain patients over the edge from chronic inflammation into cancer. For now, the presence of certain markers like persistent salivary gland swelling, low levels of a blood protein called complement, and specific antibody patterns can help identify people at higher risk who benefit from closer monitoring.
A similar pattern plays out in Hashimoto’s thyroiditis, where chronic immune attack on the thyroid creates conditions for thyroid MALT lymphoma. The common thread is always the same: years of relentless immune activity in a specific organ, creating a bed of abnormal lymphoid tissue where cancer can eventually take root.
Do Autoimmune Treatments Increase the Risk?
This is a real concern for people taking immunosuppressive medications. A large study of over 118,000 patients treated with TNF-alpha inhibitors (a class of biologic drugs commonly used for conditions like rheumatoid arthritis and inflammatory bowel disease) found that the rate of non-Hodgkin lymphoma in these users was about 3.7 times higher than expected for the general population. The risk was even more pronounced in younger patients aged 15 to 39, where it jumped to roughly 7 times higher than expected.
Certain types of TNF inhibitors carried more risk than others. Patients treated with antibody-based versions of these drugs had about 1.5 times the lymphoma risk compared to those on a different formulation, with the difference more apparent in women than men. These findings don’t necessarily mean the medications themselves are the sole cause. Untangling the contribution of the drug from the contribution of the underlying autoimmune disease, which independently raises lymphoma risk, is notoriously difficult. But the data is strong enough that it’s a factor worth being aware of.
How Doctors Tell Them Apart
Distinguishing a lymphoma from an autoimmune flare can be challenging, especially when both involve swollen lymph nodes. Reactive lymph nodes, the kind that swell during an autoimmune flare or infection, contain a diverse mix of immune cells responding to a stimulus. Lymphoma nodes, by contrast, are dominated by a single clone of cells, all genetically identical copies of one rogue lymphocyte.
Pathologists identify this difference through a combination of tissue examination under a microscope, protein markers on the cell surface, and molecular testing that checks whether the immune cells’ DNA has been rearranged in a uniform, clonal pattern. Reactive (non-cancerous) lymph tissue shows polyclonal rearrangement, meaning many different cells with many different antibody configurations. Lymphoma tissue shows clonal rearrangement, a single pattern repeated across the cell population. When a biopsy sample is small or damaged, molecular testing becomes especially important for making the right call.
Certain red flags help distinguish lymphoma from a typical autoimmune flare. Unexplained fevers, drenching night sweats, and unintentional weight loss of more than 10% of body weight, collectively known as “B symptoms,” are classic warning signs of lymphoma. Lymph nodes that keep growing over weeks, feel rubbery or firm, and don’t respond to treatment for the underlying autoimmune condition also warrant further investigation. None of these signs are definitive on their own, but together they shift the clinical picture toward something that needs a biopsy rather than a medication adjustment.
A Shared Biological Origin
The emerging picture is that autoimmune disease and lymphoma are not just loosely associated. They share roots in the same basic problem: the immune system’s quality-control process failing. During normal development, the body eliminates lymphocytes that are either self-reactive (which would cause autoimmunity) or genetically unstable (which could lead to cancer). This process, called negative selection, acts as a checkpoint against both outcomes. When it breaks down, the result can go either way, or both.
This reframing matters because it changes how we think about monitoring and prevention. People with autoimmune diseases aren’t just dealing with inflammation. They’re living with an immune system that has already demonstrated a failure in the kind of quality control that also prevents cancer. That doesn’t mean lymphoma is inevitable; for most people with autoimmune conditions, it never develops. But it does mean that persistent, unexplained changes in symptoms deserve attention rather than being automatically chalked up to “just another flare.”